Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology—A Systematic Review
Cells · 23.07.2026 · 15 (15) · 1319
DOI: 10.3390/cells15151319 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cells, online erschienen am 23.07.2026. Verfasst von Zakhi Zafrani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Independent Researcher, Manchester SK8 6HD, UK. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hypogonadism, Reproduction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Testosterone deficiency is highly prevalent in men with obesity and type 2 diabetes mellitus and often reflects functional suppression of the hypothalamic–pituitary–gonadal (HPG) axis. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in these conditions, but their effects on male reproductive endocrinology remain incompletely defined.
Objective
To systematically review the effects of GLP-1 receptor agonists on testosterone, HPG axis hormones, and male reproductive outcomes.
Methods
A systematic review was conducted in accordance with PRISMA 2020 guidelines. PubMed/MEDLINE, Cochrane, and Google Scholar were searched (January 2021–January 2026) for studies evaluating GLP-1 RA therapy in adult men with reported endocrine or reproductive outcomes.
Results
Eight studies met inclusion criteria, including one randomised placebo-controlled crossover trial and six observational or interventional studies. In men with obesity, type 2 diabetes, or functional hypogonadism, GLP-1 RAs were associated with modest increases in testosterone and improvements in erectile function or selected semen parameters. In contrast, a placebo-controlled trial in healthy eugonadal men showed no significant endocrine or reproductive effects. Responses appeared dependent on baseline metabolic status.
Conclusions
GLP-1 RAs are associated with improvements in male reproductive endocrinology in metabolically compromised populations with metabolic hypogonadism while remaining neutral in healthy individuals. Larger prospective studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Independent Researcher, Manchester SK8 6HD, UK.
- Department of Clinical and Surgical Andrology, Centre of Reproductive Medicine and Andrology, Münster University Hospital, 48149 Munster, Germany.
ORCID-Profile: Zakhi Zafrani
Zitieren
APA
Zafrani, Z., Khan, S. S., & Zitzmann, M. (2026). Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology—A Systematic Review. Cells, 15(15), 1319. https://doi.org/10.3390/cells15151319
Vancouver
Zafrani Z, Khan SS, Zitzmann M. Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology—A Systematic Review. Cells. 2026;15(15):1319. doi:10.3390/cells15151319
BibTeX
@article{Zafrani2026,
author = {Zafrani, Zakhi and Khan, Sarah Suleman and Zitzmann, Michael},
title = {Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology—A Systematic Review},
journal = {Cells},
year = {2026},
volume = {15},
number = {15},
pages = {1319},
doi = {10.3390/cells15151319}
}
EUVIMED